基因组分析公司Bionano Genomics（BNGO）今日盘前股价大涨24.06%，主要受益于公司发布的第一季度财报好于市场预期。
根据公司公布的财报，截至3月31日的第一季度，Bionano Genomics调整后每股亏损1.15美元，远低于分析师平均预期的3.02美元亏损。尽管公司营收为646万美元，同比下降26.4%，但仍高于市场预期的623万美元。本季度公司净亏损为310万美元。
尽管公司业绩仍处于亏损状态，但亏损幅度的显著收窄显然提振了投资者信心。值得注意的是，分析师对该公司的平均评级为"持有"，其中1个为"强烈买入"或"买入"，2个为"持有"，没有"卖出"或"强烈卖出"评级。华尔街分析师给予Bionano Genomics未来12个月的目标价中位数为7.00美元。这些因素可能共同推动了公司股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.